ADIAL PHARMACEUTICALS, INC. 8-K

What Happened

• On March 3, 2026, Adial Pharmaceuticals, Inc. announced a collaboration framework with Molteni Farmaceutici for a proposed exclusive partnership to commercialize AD04 in Europe. The framework is subject to a final definitive agreement and gives Molteni a period of exclusivity to evaluate feasibility, conduct due diligence, planning, and prepare for a potential European launch.
• On February 26, 2026, the Company called a Special Meeting of Stockholders but did not have a quorum, so the meeting could not be convened. Under an Inducement Agreement dated November 25, 2025, Adial must continue to call additional stockholder meetings every 90 days until stockholder approval is obtained or the related warrants are no longer outstanding.

Key Details

• Collaboration framework announced: March 3, 2026 (press release).
• Financial terms expected in a definitive agreement: an upfront payment, development/commercial milestone payments, and tiered royalties to Adial on European AD04 net sales (high single digits to low double digits).
• Estimated potential aggregate value from royalties and milestones: nearly $60 million over time, contingent on AD04 progressing through clinical development and being launched in Europe.
• Warrant/approval specifics: up to 13,823,512 shares issuable upon exercise of “New Warrants”; Company must re‑call meetings every 90 days until stockholder approval or warrants expire.

Why It Matters

• The Molteni framework, if finalized, could create a new revenue path for Adial through upfronts, milestones, and royalties tied to AD04’s European commercialization — but the ~$60M estimate is contingent on successful clinical and commercial progress.
• The failed special meeting matters to investors because the Company remains obligated to repeatedly seek shareholder approval related to nearly 13.8 million potential shares tied to the Inducement Agreement. That process could affect the timing of potential dilution and corporate planning until approval is resolved or the warrants lapse.